AVTR 📈 Avantor - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05352A1007
AVTR: Chemicals, Reagents, Lab Supplies, Equipment, Instruments, Services
Avantor Inc, a company with a rich history dating back to 1904, operates at the intersection of multiple industries, including biopharma, healthcare, education, government, advanced technologies, and applied materials. With a presence in the Americas, Europe, Asia, the Middle East, and Africa, the company has established itself as a provider of mission-critical products and services. Its portfolio includes a wide range of materials and consumables, such as high-purity chemicals and reagents, lab products, and customized excipients, which are essential for various research and production activities.
The company's product offerings also encompass equipment and instrumentation, including filtration systems, virus inactivation systems, and analytical instruments. These products are designed to support research, development, and production processes in fields like biopharma, healthcare, and education. Additionally, Avantor provides a range of services, including onsite lab and production support, clinical services, equipment procurement, and sourcing. This comprehensive suite of services enables customers to focus on their core activities while relying on Avantor for specialized support.
Avantor's services extend to scientific research support, where the company offers expertise in areas like DNA extraction, bioreactor servicing, and compound management. These services are critical for researchers and scientists working on complex projects, and Avantor's capabilities help accelerate discovery and development. With its headquarters in Radnor, Pennsylvania, and a global presence, Avantor is well-positioned to support customers across various industries and geographies. The company's website, https://www.avantorsciences.com, provides further information on its products, services, and capabilities.
As a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol AVTR, Avantor is committed to delivering value to its shareholders. With a common stock ISIN of US05352A1007 and a classification under the GICS Sub Industry of Life Sciences Tools & Services, the company operates within a specific segment of the life sciences industry. This focus enables Avantor to concentrate on developing and delivering specialized products and services that meet the evolving needs of its customers, driving growth and innovation in the process.
Additional Sources for AVTR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AVTR Stock Overview
Market Cap in USD | 15,035m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2019-05-17 |
AVTR Stock Ratings
Growth 5y | 3.59% |
Fundamental | 14.5% |
Dividend | - |
Rel. Strength Industry | -229 |
Analysts | 4.14/5 |
Fair Price Momentum | 19.37 USD |
Fair Price DCF | 28.40 USD |
AVTR Dividends
No Dividends PaidAVTR Growth Ratios
Growth Correlation 3m | -82.8% |
Growth Correlation 12m | -8.5% |
Growth Correlation 5y | -2.7% |
CAGR 5y | 3.08% |
CAGR/Mean DD 5y | 0.11 |
Sharpe Ratio 12m | -0.26 |
Alpha | -32.48 |
Beta | 0.95 |
Volatility | 29.57% |
Current Volume | 11025.9k |
Average Volume 20d | 6053.8k |
As of December 21, 2024, the stock is trading at USD 21.21 with a total of 11,025,884 shares traded.
Over the past week, the price has changed by -5.02%, over one month by +5.31%, over three months by -21.42% and over the past year by -6.65%.
Neither. Based on ValueRay Fundamental Analyses, Avantor is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.53 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AVTR as of December 2024 is 19.37. This means that AVTR is currently overvalued and has a potential downside of -8.68%.
Avantor has received a consensus analysts rating of 4.14. Therefor, it is recommend to buy AVTR.
- Strong Buy: 9
- Buy: 7
- Hold: 6
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AVTR Avantor will be worth about 21.2 in December 2025. The stock is currently trading at 21.21. This means that the stock has a potential downside of -0.19%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 27.3 | 28.8% |
Analysts Target Price | 24.1 | 13.4% |
ValueRay Target Price | 21.2 | -0.2% |